Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

Your steroid medication and emergency card - patient information

Description: This factsheet explains what adrenal insufficiency and adrenal crisis are, the symptoms to look out for and what to do if
Url: /Media/UHS-website-2019/Patientinformation/Medicinestherapiesandanaesthetics/Your-steroid-medication-and-emergency-card-3997-PIL.pdf

Sexual function after radical cystectomy - Information for women - patient information

Description: This factsheet explains how a radical cystectomy can affect sexual function and ways to help manage these changes.
Url: /Media/UHS-website-2019/Patientinformation/Surgery/Sexual-function-after-radical-cystectomy-Information-for-women-3743-PIL.pdf

Elranatamab

Description: Chemotherapy Protocol ELRANATAMAB This protocol may require funding Regimen • Elranatamab Indication • Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Elranatamab-Ver2.pdf

Cytoreductive surgery for gynaecological cancer - patient information

Description: This factsheet explains what cytoreductive surgery is, what the procedure involves and what the possible risks are.
Url: /Media/UHS-website-2019/Patientinformation/Womenshealth/Cytoreductive-surgery-for-gynaecological-cancer-3842-PIL.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indication • Treatment of adult patients with relapsed or refractory diffu
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Epcoritamab -Cycle 1 (Priming)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Priming) Indication • Treatment of adult patients with relapsed or refractory diffu
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

Tarlatamab (EAMS)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) Tarlatamab (EAMS) Regimen • SCLC – Tarlatamab (EAMS) Indication • Tarla
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Tarlatamab-EAMS-Ver-1.0.pdf

Preparing for surgery - patient information

Description: This booklet contains important information on how to prepare for surgery.
Url: /Media/UHS-website-2019/Patientinformation/Surgery/Preparing-for-surgery-3167-PIL.pdf

Your medication after the birth of your baby - patient information

Description: A guide to your medication after the birth of your baby.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Your-medication-after-the-birth-of-your-baby.pdf

Glofitamab-Obinutuzumab

Description: Chemotherapy Protocol LYMPHOMA GLOFITAMAB-OBINUTUZUMAB Regimen • Lymphoma-Glofitamab-Obinutuzumab Indication • Treatment of adul
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Glofitamab-Obinutuzumab.pdf

71 to 80 of 105

Previous … 6 7 8 9 10 … Next